مرکز اطلاعات علمی Scientific Information Database (SID) - Trusted Source for Research and Academic Resources

video

مرکز اطلاعات علمی Scientific Information Database (SID) - Trusted Source for Research and Academic Resources

sound

مرکز اطلاعات علمی Scientific Information Database (SID) - Trusted Source for Research and Academic Resources

Persian Version

مرکز اطلاعات علمی Scientific Information Database (SID) - Trusted Source for Research and Academic Resources

View:

100
مرکز اطلاعات علمی Scientific Information Database (SID) - Trusted Source for Research and Academic Resources

Download:

73
مرکز اطلاعات علمی Scientific Information Database (SID) - Trusted Source for Research and Academic Resources

Cites:

Information Journal Paper

Title

Efficacy of Intravitreal Bevacizumab for the Treatment of Zone I Type 1 Retinopathy of Prematurity

Pages

  29-33

Abstract

 Purpose: To describe the efficacy of Intravitreal Bevacizumab for the Treatment of type 1 Retinopathy of Prematurity (ROP) in Zone I. Methods: Preterm infants with type 1 ROP in Zone I (Zone I ROP, any stage with plus disease or Zone I ROP, stage 3 without plus disease) were enrolled in this prospective study. Intravitreal Bevacizumab (0. 625 mg/0. 025 ml) was injected under topical anesthesia. Patients were followed weekly for 4 weeks and then biweekly till 90 weeks gestational age. Results: Seventy eyes of 35 patients with type 1 ROP in Zone I were enrolled. At a gestational age of 90 weeks, ROP regressed with complete or near‑ complete peripheral retinal vascularization, in 82. 9% of eyes after a single injection and in 92. 9% of eyes after up to two injections. In five eyes (7. 1%), ROP progressed to stage 4B or 5, so surgical management was required. There were no major complications such as endophthalmitis, cataract, or vitreous hemorrhage after injection. Conclusion: Intravitreal Bevacizumab injection is an effective method for the management of patients with Zone I ROP requiring Treatment; however, some cases may progress to more advanced stages and require surgical management. Close monitoring for recurrence or progression is necessary. Eyes with persistent Zone I ROP may progress to advanced stages when treated with Intravitreal Bevacizumab injection and re‑ Treatment may be needed.

Cites

  • No record.

    • References

    Cite

    APA: Copy

    KARKHANEH, REZA, TORABI, HAMIDREZA, Khodabandeh, Alireza, ROOHIPOOR, RAMAK, & RIAZI ESFAHANI, MOHAMMAD. (2018). Efficacy of Intravitreal Bevacizumab for the Treatment of Zone I Type 1 Retinopathy of Prematurity. JOURNAL OF OPHTHALMIC AND VISION RESEARCH, 13(1), 29-33. SID. https://sid.ir/paper/311821/en

    Vancouver: Copy

    KARKHANEH REZA, TORABI HAMIDREZA, Khodabandeh Alireza, ROOHIPOOR RAMAK, RIAZI ESFAHANI MOHAMMAD. Efficacy of Intravitreal Bevacizumab for the Treatment of Zone I Type 1 Retinopathy of Prematurity. JOURNAL OF OPHTHALMIC AND VISION RESEARCH[Internet]. 2018;13(1):29-33. Available from: https://sid.ir/paper/311821/en

    IEEE: Copy

    REZA KARKHANEH, HAMIDREZA TORABI, Alireza Khodabandeh, RAMAK ROOHIPOOR, and MOHAMMAD RIAZI ESFAHANI, “Efficacy of Intravitreal Bevacizumab for the Treatment of Zone I Type 1 Retinopathy of Prematurity,” JOURNAL OF OPHTHALMIC AND VISION RESEARCH, vol. 13, no. 1, pp. 29–33, 2018, [Online]. Available: https://sid.ir/paper/311821/en

    Related Journal Papers

  • No record.

    • Related Seminar Papers

  • No record.

    • Related Plans

  • No record.

    • Recommended Workshops






    Move to top
    telegram sharing button
    whatsapp sharing button
    linkedin sharing button
    twitter sharing button
    email sharing button
    email sharing button
    email sharing button
    sharethis sharing button